GlassScriptPhysician profile
Jaime Kratz
NPI 1851391411
$134,889.40
in general payments reported to CMS, 2019-2025
39 companies · $15K in 2025
The $15K reported for 2025 was more than what 90% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $9,256 · 2021: $8,031 · 2022: $23K · 2023: $35K · 2024: $43K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Food and Beverage: $11K · Travel and Lodging: $3,438 · Consulting Fee: $2,228 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,315.71 |
| Food and Beverage | $11,274.45 |
| Travel and Lodging | $3,438.27 |
| Consulting Fee | $2,227.62 |
| Education | $203.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $56,743.53 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $32,867.38 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $23,570.87 | 2019-2025 | |
| Amgen INC. | $12,498.58 | 2021-2025 | Tezspire, Actimmune |
| Regeneron Healthcare Solutions, INC. | $2,450.31 | 2019-2025 | Dupixent |
| Csl Behring | $772.04 | 2019-2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $731.20 | 2019-2025 | |
| Octapharma USA, INC. | $721.52 | 2020-2025 | Cutaquig, Panzyga |
| Takeda Pharmaceuticals U.S.A., INC. | $704.28 | 2020-2025 | Hyqvia, Cuvitru |
| Genentech USA, INC. | $695.65 | 2019-2025 | Xolair |
| Pfizer INC. | $420.78 | 2019-2025 | |
| Leo Pharma INC. | $311.73 | 2022-2025 | Adbry, Anzupgo |
| Abbvie INC. | $232.94 | 2021-2024 | |
| Grifols USA, LLC | $217.91 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Pharming Healthcare, INC. | $196.49 | 2020-2025 | Ruconest |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $191.10 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.83 | 2019-2022 | |
| Galderma Laboratories, L.P. | $171.96 | 2025 | Nemluvio |
| Biocryst US Sales Co., LLC | $146.90 | 2021-2025 | Orladeyo |
| Optinose US, INC. | $138.03 | 2019-2025 | |
| Shire North American Group INC | $136.06 | 2019 | |
| Kaleo, INC. | $130.34 | 2020-2023 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $112.96 | 2019-2021 | |
| Phadia US INC. | $105.30 | 2021-2025 | Immunocap |
| Aimmune Therapeutics, INC. | $97.80 | 2020-2022 | |
| Adma Biomanufacturing LLC | $72.05 | 2022-2023 | |
| Lilly USA, LLC | $46.39 | 2025 | Ebglyss |
| Blueprint Medicines Corporation | $38.26 | 2024-2025 | Ayvakit |
| Incyte Corporation | $36.12 | 2021-2023 | Opzelura |
| Circassia INC. | $28.74 | 2020 | |
| Arcutis Biotherapeutics, INC. | $22.41 | 2025 | Zoryve |
| Hikma Pharmaceuticals USA | $21.09 | 2023 | Ryaltris |
| Horizon Therapeutics Plc | $19.12 | 2021 | |
| Covis Pharma Gmbh | $14.67 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.95 | 2025 | Xhance |
| Alk-Abello, INC | $12.07 | 2020 | |
| Novo Nordisk INC | $12.04 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Kratz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.